Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02678195
Recruitment Status : Active, not recruiting
First Posted : February 9, 2016
Last Update Posted : September 4, 2019
Sponsor:
Collaborators:
University of North Carolina
University of Washington
Information provided by (Responsible Party):
Save the Children

Brief Summary:
This clinical trial evaluates the duration of treatment of chest-indrawing pneumonia in children. Half the children will receive 3 days of amoxicillin dispersible tablets (DT) and then 2 days of placebo, while the other half will receive 5 days of amoxicillin DT.

Condition or disease Intervention/treatment Phase
Pneumonia Drug: Amoxicillin Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind Randomized Controlled Clinical Trial of 3 Days Versus 5 Days Amoxicillin Dispersible Tablets for Chest-indrawing Childhood Pneumonia Among Children 2-59 Months of Age Presenting to Kamuzu Central Hospital in Lilongwe, Malawi
Actual Study Start Date : March 2016
Actual Primary Completion Date : April 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: 3 days amoxicillin + 2 days placebo
3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
Drug: Amoxicillin
Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Drug: Placebo
Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Active Comparator: 5 days amoxicillin
5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
Drug: Amoxicillin
Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily




Primary Outcome Measures :
  1. Proportion of children failing treatment [ Time Frame: 6 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 59 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, 2 to 59 months of age.
  • History of cough <14 days or difficult breathing with chest-indrawing.
  • Ability and willingness of child's caregiver to provide informed consent and to be available for follow-up for the planned duration of the study, including accepting a home visit if he/she fails to return to Kamuzu Central Hospital (KCH) for a scheduled study follow-up visit.

Exclusion Criteria:

  • If chest-indrawing observed at screening resolves after bronchodilator challenge, among those with wheeze at screening.
  • Severe respiratory distress (e.g., grunting, nasal flaring, head nodding, or severe chest-indrawing).
  • Presence of World Health Organization (WHO) Integrated Management of Childhood Illness (IMCI) danger signs including: lethargy or unconsciousness, convulsions, vomiting everything, or inability to drink or breastfeed.
  • Hypoxia (SaO2 < 90% on room air, as assessed by a Lifebox pulse oximeter).
  • Stridor when calm.
  • HIV-1 seropositivity or HIV-1 exposure, assessed as follows:

    • An HIV-positive result upon rapid antibody test will exclude any child from this study.
    • If a child is less than 12 months or age with a positive rapid test result, the child will be referred to receive additional confirmatory HIV testing (e.g., dried blood spot filter paper test) and follow-up from KCH staff, as per standard of care. Even if the confirmatory HIV testing subsequently shows that child is HIV-negative, he or she will remain excluded from the study.
    • If a child is less than 24 months of age and has an HIV-negative result upon rapid antibody test, the child's biological mother's HIV status will need to be assessed. If the mother is HIV-positive, the child will be excluded. If the mother has a documented HIV-negative test result from within the past 6 weeks, the child will be included. If the mother does not have documentation of an HIV-negative test result, she will be tested via rapid antibody testing to determine the child's eligibility for this study.
    • If a child is over 24 months of age, an HIV-negative rapid antibody test is required for inclusion in the study.
    • Note: If a child has documentation of an HIV-negative test result from within the past 6 weeks, that test result will be used for the child's eligibility assessment according to the algorithm described above.
  • Severe acute malnutrition (i.e., weight for height/length < -3 SD, mid-upper arm circumference <115 mm, or edema).
  • Possible tuberculosis (coughing for more than 14 days).
  • Severe anemia, classified by WHO pocketbook guidelines (i.e., severe palmar pallor or hemoglobin <8.0 g/dL)
  • Severe malaria, classified by WHO pocketbook guidelines (e.g., positive malaria rapid diagnostic test (mRDT) with any danger sign, stiff neck, abnormal bleeding, clinical jaundice, or hemoglobinuria)
  • Known allergy to penicillin or amoxicillin.
  • Receipt of an antibiotic treatment in the 48 hours prior to the study based on caregiver's self-report and/or documentation in child's medical record.
  • Hospitalized within 14 days prior to the study.
  • Living outside Lilongwe urban area, the study catchment area.
  • Any medical or psychosocial condition or circumstance that, in the opinion of the investigators, would interfere with the conduct of the study or for which study participation might jeopardize the child's health.
  • Any non-pneumonia acute medical illness which requires antibiotic treatment per local standard of care.
  • Participation in a clinical study of another investigational product within 12 weeks prior to randomization or planning to begin participation during this study.
  • Prior participation in an Innovative Treatments in Pneumonia (ITIP) study during a previous pneumonia diagnosis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02678195


Locations
Layout table for location information
Malawi
Bwaila District Hospital
Lilongwe, Malawi
Kamuzu Central Hospital
Lilongwe, Malawi
Sponsors and Collaborators
Save the Children
University of North Carolina
University of Washington
Investigators
Layout table for investigator information
Principal Investigator: Amy Ginsburg, MD, MPH Save the Children
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Save the Children
ClinicalTrials.gov Identifier: NCT02678195    
Other Study ID Numbers: ITIP2
First Posted: February 9, 2016    Key Record Dates
Last Update Posted: September 4, 2019
Last Verified: September 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Amoxicillin
Anti-Bacterial Agents
Anti-Infective Agents